Feverfew: Side Effects and Post-Feverfew Syndrome

Feverfew is, by the standards of things people take daily for months, a gentle herb. In the largest trial, side effects possibly related to treatment occurred in 8.4 percent of people on feverfew and 10.2 percent on placebo — that is, slightly less often on the active drug (Diener 2005). The Cochrane review of all six trials found only “mild and transient adverse events, most commonly gastrointestinal complaints and mouth ulcers,” and concluded that feverfew “is not associated with any major safety concerns” (Wider 2015).

That is the honest headline, and it belongs up front rather than buried under warnings. But short trials in selected patients do not capture everything, and feverfew has four specific issues that a generic “consult your doctor” paragraph would fail you on: the withdrawal reaction, daisy-family allergy, mouth ulcers from chewing the leaf, and its antiplatelet effect. This page covers all four properly, and what is known about each.

Table of Contents

  1. The Overall Safety Picture
  2. Post-Feverfew Syndrome
  3. Stopping Gradually and the Rebound Risk
  4. Mouth Ulcers and Oral Irritation
  5. Asteraceae Allergy and Cross-Reactivity
  6. Antiplatelet Effects, Anticoagulants and Surgery
  7. Digestive Side Effects
  8. Pregnancy, Breastfeeding and Fertility
  9. Who the Research Raises Concerns For
  10. Drug Interactions
  11. Warning Signs That Need Medical Attention
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Overall Safety Picture

What the trial evidence actually supports:

The limits of that evidence matter too. The longest trials ran about nine months as crossovers, in which each person took feverfew for only about four months (Murphy 1988), and the largest parallel trial treated people for 16 weeks (Diener 2005), so there are essentially no data on multi-year use. Trials exclude pregnant women, children, and people with significant comorbidity. And trial populations use a defined product, whereas real-world users take whatever they bought — a category with documented 160-fold variation in parthenolide delivered (Nelson 2002). Absence of a signal in a 16-week trial of a controlled extract is genuinely reassuring; it is not the same as proof of long-term safety for every product.

Post-Feverfew Syndrome

This is the caution most likely to catch you out, because it happens when you stop, and nothing on a supplement label warns you about it.

What it is: a withdrawal-type cluster reported in people who have taken feverfew regularly for a long period and then stop abruptly. The described features are:

Where it comes from. The evidence base is thinner than the confident name suggests, and honesty requires saying so. The primary observation is in the 1985 BMJ trial (Johnson 1985), where 17 people who had been eating fresh feverfew daily were randomised to capsules of freeze-dried feverfew or placebo. Those switched to placebo — i.e. abruptly withdrawn from feverfew without knowing it — had a significant increase in the frequency and severity of headache, nausea and vomiting, “with the emergence of untoward effects during the early months of treatment.” Those untoward effects are the origin of the syndrome. The term “post-feverfew syndrome” itself entered the herbal and review literature from that observation and from subsequent user reports, and it is repeated in review articles (Pareek 2011) rather than resting on a dedicated study.

The review describes it in these words: people who switched to placebo “after taking feverfew for several years experienced a cluster of nervous system reactions (eg, headaches, insomnia, joint pain, nervousness, poor sleep patterns, stiffness, tension, tiredness) along with muscle and joint stiffness, often referred to as ‘postfeverfew’ syndrome” (Pareek 2011).

So the correct status is: a well-described clinical observation from a controlled trial, plus consistent user reports, without a dedicated withdrawal study. That explains why gradual stopping is commonly described, but it is not enough for incidence figures: no study has measured how often the syndrome occurs, so a quoted rate has no study behind it.

Why it might happen. Two plausible accounts, neither proven:

  1. Nerve resensitisation. In rodent studies (rat and mouse trigeminal nerve cells, and cells engineered to carry the channel), parthenolide acted on the TRPA1 channel of trigeminal nerve endings as a partial agonist that then desensitised them, leaving the pain fibres unresponsive — “defunctionalised” (Materazzi 2013). This has not been shown in people. Remove the compound and those terminals recover their sensitivity. A period of heightened reactivity as they come back online is exactly what you would predict, and it mirrors what happens when capsaicin treatment stops.
  2. Unmasking. If feverfew was genuinely suppressing attacks, stopping simply returns you to baseline — which feels much worse by contrast, and can be over-interpreted as a rebound. The 1985 trial cannot fully distinguish these, because the placebo group's deterioration is consistent with both.

Either way, the practical picture is the same: the reported problems are tied to stopping abruptly.

Stopping Gradually and the Rebound Risk

The withdrawal problems described above followed sudden stops. The 1985 trial’s placebo group was switched off feverfew abruptly; a review notes that “the abrupt discontinuation of feverfew caused incapacitating headaches in some patients” (Pareek 2011); and the US National Library of Medicine’s breastfeeding-medicines database (LactMed) states that “rebound headaches can occur with rapid discontinuation.” For that reason, reducing the dose gradually over a few weeks, rather than stopping at once, is the practice commonly described for people who have taken feverfew daily for more than a few weeks. No study has tested any particular taper schedule, and none of the sources on this page sets one out.

Three related points:

Mouth Ulcers and Oral Irritation

This is feverfew's signature adverse effect, and it is one of the two most commonly reported in the trial literature (Wider 2015).

What happens: painful aphthous-type ulcers inside the mouth, a sore or inflamed tongue and lips, swelling of the oral tissues, and sometimes a temporary loss or alteration of taste. It usually resolves within days to a couple of weeks after stopping.

A review reports that “in a larger series of feverfew users, 18% reported adverse effects, the most serious being mouth ulceration (11%),” and that feverfew “can induce more widespread inflammation of the oral mucosa and tongue, often with lip swelling and loss of taste” (Pareek 2011).

Who gets it: overwhelmingly people who chew fresh leaves, which is the traditional method. This makes chemical sense — parthenolide is a reactive electrophile that binds covalently to protein thiol groups, and pressing raw leaf against the mucosa delivers it at high local concentration to a delicate tissue.

What changes the risk:

Asteraceae Allergy and Cross-Reactivity

Feverfew belongs to the Asteraceae (Compositae) family — the daisy family, one of the largest plant families on earth. Family membership matters here because the sesquiterpene lactones that make these plants pharmacologically interesting also make them a leading cause of plant contact allergy in Europe.

Plants that commonly cross-react:

Feverfew is specifically recognised as “an important sensitizer in European Compositae-allergic patients, mainly because of its content of the sesquiterpene lactone parthenolide” (Paulsen 2010). That Danish study makes a further point worth knowing: when feverfew-allergic patients were patch tested with creams containing a parthenolide-depleted feverfew extract, four of seven still reacted — so removing the main sensitiser did not reliably make the extract safe for already-sensitised people. Occupational contact dermatitis to Tanacetum parthenium is also documented (Hashimoto 2019).

What reactions look like: most are contact reactions — itchy rash, redness, swelling where the plant touched skin, sometimes an airborne pattern on the face and neck in gardeners. Systemic allergic reactions to oral feverfew are rare but possible; lip, tongue or throat swelling, wheeze, or faintness are signs of a severe allergic reaction that hospitals treat as an emergency.

What this means in practice: the cross-reactivity data concern people with known ragweed, chrysanthemum, chamomile or general Compositae allergy. In that group the first signs of a reaction are rash, itching or swelling in the mouth; handling the fresh plant is the main route for contact reactions; and the gravest risk is for people who have had anaphylaxis to a plant in this family.

Antiplatelet Effects, Anticoagulants and Surgery

This caution is not theoretical hand-waving imported from a generic herb list — it comes directly from feverfew's own pharmacology, studied in human platelets.

Feverfew extracts inhibit platelet aggregation and the secretion of granules from platelets and white blood cells, blocking serotonin release triggered by ADP, adrenaline, arachidonate, collagen and thromboxane analogues (Heptinstall 1985). The mechanism appears to be neutralisation of sulphydryl groups on platelet proteins (Heptinstall 1987), and purified parthenolide reproduces the effect (Groenewegen 1990). Importantly, this works differently from aspirin — thromboxane synthesis is not inhibited — so the effects are not redundant and could in principle add together. A small 1982 study reported altered platelet aggregation responses in people actually taking feverfew for migraine (Biggs 1982).

What the platelet findings mean alongside other medicines:

To keep this proportionate: no serious bleeding event attributable to feverfew appears in the trial literature, and the trials found no excess of adverse events overall. The concern is mechanistic and precautionary, and it is most relevant to people already on blood thinners or facing a procedure.

Digestive Side Effects

The other commonly reported category in trials. Nausea, indigestion, bloating, abdominal discomfort, wind and occasionally diarrhoea — generally mild and often settling within a couple of weeks.

Approaches described for reducing it: taking it with food; splitting the dose across the day rather than taking it all at once (the best trial dosed three times daily anyway); and starting at a lower dose and building up. Symptoms that persist past a few weeks suggest feverfew does not suit that person. Bitter herbs commonly cause this, and feverfew is notably bitter.

One longer-term theoretical concern has been raised in the review literature: feverfew has cyclooxygenase-2 (COX-2) inhibiting activity, and one systematic review flagged this as a reason for caution with very long-term dosing, particularly in people with coronary disease (Saranitzky 2009). In the review’s words, “there is some potential for concern with long-term dosing given its cyclooxygenase-2 inhibiting effects and longer-term studies will be needed to ameliorate these concerns in coronary disease patients.” No clinical harm has been demonstrated.

Pregnancy, Breastfeeding and Fertility

Pregnancy is the firmest caution on this page. Feverfew “is traditionally contraindicated in pregnancy but there are no studies confirming this warning” (Yao 2006); for a herb whose overall safety record is otherwise good, the concern rests on two independent reasons.

Traditional use. Feverfew has a long folk reputation as an emmenagogue — a substance used to bring on menstruation — and was historically given to assist labour and expel the placenta. Traditional use is not evidence of efficacy, but a plant traditionally used to affect the uterus is a plant whose uterine effects are the concern in pregnancy.

Experimental data. The only reproductive screening study is in rats, and its results do not reassure. Female rats were dosed orally with 839 mg/kg feverfew daily on gestation days 1–8 or 8–15. Fetuses exposed on days 8–15 were smaller than controls, apparently because of an increased frequency of runts in treated litters; pre-implantation loss appeared increased in the early-exposure group though not significantly; and feverfew induced toxicity in cultured rat embryos. The authors' conclusion was that a comprehensive reproductive study is warranted (Yao 2006).

Read that carefully: it is an animal screen at a high dose, and it is not evidence that feverfew causes birth defects in humans. What it is, is the only experimental look anyone has taken, and it came back with enough of a signal that the researchers asked for a full study — which has not been done. Set against a measured benefit of 0.6 attacks per month, that unresolved animal signal weighs heavily in pregnancy.

Breastfeeding: the US National Library of Medicine’s LactMed database states that “no data exist on the excretion of any components of feverfew into breastmilk or on the safety and efficacy of feverfew in nursing mothers or infants,” and that, because of the lack of safety data, “some reviewers recommend against its use during breastfeeding.” The same entry notes that rebound headaches can occur with rapid discontinuation.

Trying to conceive: organ formation (organogenesis) is well underway before most pregnancies are confirmed, and the rat data implicated the gestation day 8–15 window, so exposure in an early, not-yet-confirmed pregnancy is the relevant concern.

Who the Research Raises Concerns For

GroupWhyStrength of the concern
Pregnant womenEmmenagogue tradition plus animal reproductive-toxicity signalFirmest concern on this page
Breastfeeding womenNo safety dataSome reviewers recommend against use (LactMed)
Known Asteraceae/Compositae allergyDocumented cross-reactivity; parthenolide is a recognised sensitiserHigh; gravest after past anaphylaxis to this plant family
ChildrenNot adequately studied at any ageNo safety data
People with bleeding disorders or low plateletsAntiplatelet activityHigh
Anyone within two weeks of planned surgeryBleeding riskA tapered stop about two weeks before is commonly described
People on warfarin, direct oral anticoagulants, aspirin or clopidogrelAdditive antiplatelet effectPlausible, not tested in trials
People who chew the fresh leafMouth ulcers; uncontrolled dose; misidentification riskCapsules avoid mouth contact
People with new, severe or changing headacheMay signal another conditionDoctors treat such headaches as needing a diagnosis

Drug Interactions

Feverfew has fewer documented interactions than its reputation suggests, and the ones that matter follow from its pharmacology rather than from case reports.

Warning Signs That Need Medical Attention

Signs that hospitals treat as urgent in someone taking feverfew:

Signs usually handled with a routine medical review are a persistent rash, mouth ulcers that do not settle after a switch to capsules, or digestive symptoms lasting beyond a few weeks. Jaundice (yellow skin or eyes) or dark urine are signs of liver injury that hospitals treat as urgent.

Supplements are omitted from medication lists constantly, and feverfew is one where the omission genuinely matters: before surgery or dental extraction, when an anticoagulant is started, and in pregnancy or when planning one.

Key Research Papers

Every identifier was verified live against NCBI E-utilities before being written here.

Withdrawal and overall tolerability

  1. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Ed.). 1985;291(6495):569–573 — PubMed PMID: 3929876 — The source of the post-feverfew withdrawal description: habitual users switched to placebo had significantly worse headache, nausea and vomiting with “untoward effects” in the early months.
  2. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2015;4(4):CD002286 — PubMed PMID: 25892430 — Only mild and transient adverse events across six trials; no major safety concerns.
  3. Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041 — PubMed PMID: 16232154 — Adverse events 8.4% versus 10.2% on placebo.
  4. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. The Lancet. 1988;2(8604):189–192 — PubMed PMID: 2899663 — Crossover trial, four months of dried feverfew leaf and four of placebo per person; 72 randomised, 60 completed; “no serious side-effects.”
  5. Nelaturi V, Viswanatha GL, Shenoy RR, Khanna S, Krishnadas N. Systematic review and meta-analysis of Tanacetum parthenium: evaluating its efficacy in migraine relief. Natural Product Research. 2025:1–8 — PubMed PMID: 41422534 — Nine trials, 899 participants.
  6. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis. Cephalalgia. 2002;22(7):523–532 — PubMed PMID: 12230594 — No dose-related effect on any safety parameter up to 18.75 mg three times daily.
  7. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305 — PubMed PMID: 15122077 — No dose-limiting toxicity; maximum tolerated dose not reached.
  8. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacognosy Reviews. 2011;5(9):103–110 — PubMed PMID: 22096324 — Review-level description of post-feverfew syndrome.
  9. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutrition. 2000;3(4A):509–514. — PubMed PMID: 11276299

Allergy and contact sensitisation

  1. Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150 — PubMed PMID: 20690937 — Four of seven feverfew-allergic patients reacted to a parthenolide-depleted cream.
  2. Hashimoto T, Yokozeki H. Occupational contact dermatitis caused by Eucalyptus species and Tanacetum parthenium. Contact Dermatitis. 2019;80(5):333–334. — PubMed PMID: 30582184
  3. Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M. Anti-inflammatory activity of parthenolide-depleted feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17(1):42–49 — PubMed PMID: 19112586 — The extract developed specifically to remove parthenolide as a skin sensitiser.

Bleeding and platelet effects

  1. Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074. — PubMed PMID: 2860288
  2. Heptinstall S, Groenewegen WA, Spangenberg P, Lösche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. Journal of Pharmacy and Pharmacology. 1987;39(6):459–465. — PubMed PMID: 2886604
  3. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553–557. — PubMed PMID: 1981582
  4. Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. The Lancet. 1982;2(8301):776. — PubMed PMID: 6125851
  5. Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103 — PubMed PMID: 22435410 — Raises the long-term COX-2 inhibition question.

Pregnancy and mechanism of rebound

  1. Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693 — PubMed PMID: 16781113 — The only experimental reproductive data; smaller fetuses and embryotoxicity in culture.
  2. Feverfew. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Institute of Child Health and Human Development; 2006– (entry revised 2022 Nov 30) — PubMed PMID: 30000921 — No data on transfer into breast milk; rebound headaches with rapid discontinuation.
  3. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750–2758 — PubMed PMID: 23933184 — Nerve defunctionalisation — the most plausible mechanism for a rebound on withdrawal.
  4. Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy. 2002;59(16):1527–1531 — PubMed PMID: 12185827 — Why trial safety data may not describe the product you bought.

PubMed Topic Searches

  1. PubMed: Feverfew adverse effects and safety
  2. PubMed: Post-feverfew syndrome and withdrawal
  3. PubMed: Compositae contact allergy
  4. PubMed: Parthenolide skin sensitisation
  5. PubMed: Herbal supplements and perioperative bleeding
  6. PubMed: Herbal medicine safety in pregnancy
  7. PubMed: Recurrent aphthous ulcers — other causes
  8. PubMed: Medication-overuse headache

Connections


Back to Table of Contents